Screener / SEC EDGAR /CIK 0000914475 /10-K filed Feb 11, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Neurocrine Biosciences Inc NBIX

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers NBIX said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $2.70B to $2.80B release Feb 11, 2026
Kept $2.70B to $2.80B release May 5, 2026
Raised $2.83B to $2.88B release Jul 30, 2026
Raised $2.90B to $2.92B release Nov 2, 2026
– Not reported yet
The company's words
® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion release Feb 11, 2026
Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion release May 5, 2026
® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion release Jul 30, 2026
® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion release Nov 2, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $2.50B to $2.60B release Feb 6, 2025
Kept $2.50B to $2.60B release May 5, 2025
Lowered $2.50B to $2.55B release Jul 30, 2025
$2.86B
10-K filed 2026-02-11
Above the range
The company's words
(valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion release Feb 6, 2025
We are reaffirming 2025 INGREZZA net sales guidance of $2.5 to $2.6 billion,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. release May 5, 2025
INGREZZA 2025 net product sales guidance narrowed from $2.5 - $2.6 billion to $2.5 - $2.55 billion reflecting double-digit volume growth partially offset by lower net price due to expanded access. release Jul 30, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $2.10B to $2.20B release Feb 7, 2024
Raised $2.25B to $2.30B release Aug 1, 2024
Raised $2.30B to $2.32B release Oct 30, 2024
$2.36B
10-K filed 2025-02-10
Above the range
The company's words
(valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion release Feb 7, 2024
(valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion release Aug 1, 2024
(valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion release Oct 30, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-07), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.